We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FOXX:NASDAQFoxx Development Holdings Inc. Analysis

Data as of 2026-05-20 - not real-time

$3.85

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is trading at $3.85, sitting at the calculated support level of $3.85 and well below the DCF fair value of $5.90, indicating a potential undervaluation. The 20‑day SMA ($4.95) and 50‑day SMA ($4.92) sit above the current price, while the 200‑day SMA ($4.78) is also higher, confirming a short‑term price compression. Technical momentum is mixed: RSI is deep in oversold territory at 24.9, suggesting a possible rebound, but the MACD histogram is negative and the signal line is bearish, warning of lingering downside pressure. Volume is increasing, providing some liquidity support, yet the 30‑day volatility is extreme at 69% and beta of 1.48 signals high market sensitivity. Fundamental metrics are weak – revenue is declining 4.4%, margins are negative, and the company reports a -78% max drawdown, underscoring financial fragility. However, recent news notes that FOXX regained Nasdaq compliance and insiders have boosted their holdings by 122%, which may reflect renewed confidence.
Given the stark contrast between the low price and the DCF estimate, the stock leans toward a value play, but the combination of negative earnings, high volatility, and a thin market cap keeps the risk profile elevated. The lack of dividend and a negative book value further limit defensive appeal. Overall, the picture is one of a speculative upside opportunity tempered by substantial downside risk, suggesting a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • RSI indicating oversold conditions
  • Price at technical support level
  • Bearish MACD histogram

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • DCF fair value suggests upside
  • Negative earnings and high volatility
  • Insider buying signals confidence

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Regained Nasdaq compliance
  • Potential turnaround from value gap
  • Long‑run industry PE average high, offering relative cheapness

Key Metrics & Analysis

Financial Health

Revenue Growth-4.40%
Profit Margin-24.62%
ROA-14.81%
P/B Ratio-2.3
Op. Cash Flow$-2177478
Free Cash Flow$4.7M
Industry P/E38.0

Technical Analysis

TrendBullish
RSI24.9
Support$3.85
Resistance$5.90
MA 20$4.95
MA 50$4.92
MA 200$4.78
MACDBearish
VolumeIncreasing
Fear & Greed Index89.16

Valuation

Fair Value$5.90
GradeUndervalued
TypeValue

Risk Assessment

Beta1.48
Volatility69.15%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.